Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)
- First Posted Date
- 2011-02-16
- Last Posted Date
- 2015-09-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 658
- Registration Number
- NCT01297270
- Locations
- 🇺🇸
1220.47.0057 Boehringer Ingelheim Investigational Site, Bradenton, Florida, United States
🇺🇸1220.47.0078 Boehringer Ingelheim Investigational Site, Fort Lauderdale, Florida, United States
🇺🇸1220.47.0086 Boehringer Ingelheim Investigational Site, Fort Lauderdale, Florida, United States
BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)
- First Posted Date
- 2011-02-16
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 37
- Registration Number
- NCT01296932
- Locations
- 🇧🇪
UNIV UZ Gent, Gent, Belgium
🇫🇷CTR Investigation Clinique, onco, Montpellier, Montpellier Cedex 5, France
🇫🇷INS Universitaire du Cancer, Toulouse, France
Single Rising Dose Study of BI 135585 XX in Health Asian Male Volunteers.
- Conditions
- Healthy
- Interventions
- Drug: BI 135585 XXDrug: Matching placebo
- First Posted Date
- 2011-02-08
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT01291732
- Locations
- 🇰🇷
1283.5.82001 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of
Bioequivalence of Two Different Capsule Types of Dabigatran
- First Posted Date
- 2011-02-07
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 180
- Registration Number
- NCT01290757
- Locations
- 🇩🇪
1160.117.1 Boehringer Ingelheim Investigational Site, Mannheim, Germany
Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-02-04
- Last Posted Date
- 2014-07-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2705
- Registration Number
- NCT01289990
- Locations
- 🇨🇦
1245.31.20018 Boehringer Ingelheim Investigational Site, Victoria, British Columbia, Canada
🇮🇪1245.31.35305 Boehringer Ingelheim Investigational Site, Co. Galway, Ireland
🇺🇸1245.31.10034 Boehringer Ingelheim Investigational Site, Rochester, New York, United States
Bioavailability and Pharmacokinetics of BI 135585 XX Administered as Tablet With and Without Food
- First Posted Date
- 2011-01-31
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 14
- Registration Number
- NCT01286571
- Locations
- 🇩🇪
1283.3.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg)
- Conditions
- Hypertension
- Interventions
- Drug: 5 mg amlodipineDrug: 40 mg telmisartanDrug: 80 mg telmisartan
- First Posted Date
- 2011-01-31
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 225
- Registration Number
- NCT01286558
- Locations
- 🇯🇵
1235.37.08 Boehringer Ingelheim Investigational Site, Itoshima, Fukuoka, Japan
🇯🇵1235.37.01 Boehringer Ingelheim Investigational Site, Chuo-ku,Tokyo, Japan
🇯🇵1235.37.05 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan
Relative Bioavailability of Empagliflozin (BI 10773) and Ramipril Administered Together Compared to Empagliflozin (BI 10773) and Ramipril Alone in Healthy Volunteers
- First Posted Date
- 2011-01-27
- Last Posted Date
- 2014-07-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 23
- Registration Number
- NCT01284621
- Locations
- 🇩🇪
1245.45.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 135585 XX in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Placebo to BI 135585
- First Posted Date
- 2011-01-25
- Last Posted Date
- 2014-11-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 72
- Registration Number
- NCT01282970
- Locations
- 🇩🇪
1283.2.1 Boehringer Ingelheim Investigational Site, Neuss, Germany
Telmisartan and Amlodipine Versus Monocomponent Tablets
- Conditions
- Hypertension
- Interventions
- Drug: Telmisartan/Amlodipine Combination Tablet
- First Posted Date
- 2011-01-19
- Last Posted Date
- 2014-03-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 28
- Registration Number
- NCT01278797
- Locations
- 🇨🇦
1235.41.0001 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada